Subcutaneous administration of testosterone. A pilot study report

Saudi Medical Journal

Volumn 27, Issue 12, 2006, Pages 1843-1846

  Al Futaisi, Abdullah M ^a   Al Zakwani, Ibrahim S ^b   Almahrezi, Abdulaziz M ^b   Morris, David ^c  

^a Department of Food Science and Nutrition   (Oman)

^b SULTAN QABOOS UNIVERSITY   (Oman)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE; TESTOSTERONE ENANTATE;

ADOLESCENT; ADULT; ARTICLE; CANADA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE SWELLING; LOCAL SKIN REACTION; LOW DRUG DOSE; MALE; PILOT STUDY; TESTOSTERONE BLOOD LEVEL; DRUG SELF ADMINISTRATION; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; HUMANS; HYPOGONADISM; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PILOT PROJECTS; SELF ADMINISTRATION; TESTOSTERONE;

EID: 39049186803     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Minto C, Howe C, Wishart S, Conway S, Handelsman D. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: Effects of ester, injection site and volume. J Pharmacol Exp Ther 1980; 281: 93-101
2. Nicholls DP, Anderson DC. Clinical aspects of androgen deficiency in man. Andrologia 1982; 14: 379-388.
3. Matsumoto AM. Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am 1994; 23: 857-875.
4. Haupt HA, Rovere GD. Anabolic steroids: A review of the literature. Am J Sports Med 1984; 12: 469-484.
5. Cantrill JA, Dewis P, Large DM, et al. Which testosterone replacement therapy? Clin Endocrinol 1984; 24: 97-107.
6. Conway AJ, Boylan LM, Howe C, et al. A randomized clinical trail of testosterone replacement therapy in hypogonadal men. Int J Androl 1988; 11: 247-264.
7. Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM. Liver damage from long-term methlytestosterone. Lancet 1977; 2: 262-263.
8. Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/andronergic steroids. Semin Liver Dis 1987; 7: 230-236.
9. Johnsen SG, Kampmann JP, Bennet EP. Enzyme induction by oral testosterone. Clin Pharmacol Ther 1976; 20: 233-237.
10. Handelsman DJ. Clinical pharmacology of testosterone pellet implants. In: Nieschlag E, Behre HM, editors. Testosterone: Action Deficiency Substitution. 2nd ed. Berlin: Springer-VerIag. 1988; p. 349-364.
11. Deansley R, Parkes AS. Further experiments on the administration of hormone by the subcutaneous implantation of tablets. Lancet 1938; 2: 606-608.
12. Snyder PJ, Lawrence, DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980; 51: 1335.
13. Maze NA, Sanders SW, Ebert CD, Meikle AW. Mimicking the circadian pattern of testosterone and metabolite levels with enhanced transdermal delivery system. In: Gurny R, Junginger H, Peppas N, editors. Pulstile Drug delivery: Current Applications and Future Trends. Stuttgart: Wiss. Verl.-Ges.; 1993. p. 73-97.
14. Synder PJ. Clinical use of androgens. Annu Rev Med 1984; 35: 207-217.
15. Mackey MA, Conway AJ, Handelsman DJ. Tolerability of intramuscular injections of testosterone ester in an oil vehicle. Hum Reprod 1995; 10: 862-865.